Hallucinations in schizophrenia and ...
Type de document :
Article dans une revue scientifique
DOI :
PMID :
URL permanente :
Titre :
Hallucinations in schizophrenia and Parkinson's disease: an analysis of sensory modalities involved and the repercussion on patients
Auteur(s) :
Llorca, Pierre-Michel [Auteur]
CHU Clermont-Ferrand
Université d'Auvergne - Clermont-Ferrand I [UdA]
Pereira, B. [Auteur]
CHU Clermont-Ferrand
Jardri, Renaud [Auteur]
Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab]
Chereau-Boudet, I. [Auteur]
CHU Clermont-Ferrand
Université d'Auvergne - Clermont-Ferrand I [UdA]
Brousse, G. [Auteur]
CHU Clermont-Ferrand
Université d'Auvergne - Clermont-Ferrand I [UdA]
Misdrahi, D. [Auteur]
Centre hospitalier Charles Perrens [Bordeaux]
Institut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
Fénelon, G. [Auteur]
Institut Mondor de Recherche Biomédicale [IMRB]
École normale supérieure - Paris [ENS-PSL]
Tronche, A.-M. [Auteur]
CHU Clermont-Ferrand
Schwan, Raymund [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Lançon, C. [Auteur]
Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants [SPMC]
Hôpital Sainte-Marguerite [CHU - APHM] [Hôpitaux Sud ]
Marques, A. [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Ulla, Miguel [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Derost, P. [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Debilly, Berangere [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Durif, Franck [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Chazeron, Ingrid De [Auteur]
Université d'Auvergne - Clermont-Ferrand I [UdA]
CHU Clermont-Ferrand
CHU Clermont-Ferrand
Université d'Auvergne - Clermont-Ferrand I [UdA]
Pereira, B. [Auteur]
CHU Clermont-Ferrand
Jardri, Renaud [Auteur]

Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab]
Chereau-Boudet, I. [Auteur]
CHU Clermont-Ferrand
Université d'Auvergne - Clermont-Ferrand I [UdA]
Brousse, G. [Auteur]
CHU Clermont-Ferrand
Université d'Auvergne - Clermont-Ferrand I [UdA]
Misdrahi, D. [Auteur]
Centre hospitalier Charles Perrens [Bordeaux]
Institut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
Fénelon, G. [Auteur]
Institut Mondor de Recherche Biomédicale [IMRB]
École normale supérieure - Paris [ENS-PSL]
Tronche, A.-M. [Auteur]
CHU Clermont-Ferrand
Schwan, Raymund [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Lançon, C. [Auteur]
Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants [SPMC]
Hôpital Sainte-Marguerite [CHU - APHM] [Hôpitaux Sud ]
Marques, A. [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Ulla, Miguel [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Derost, P. [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Debilly, Berangere [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Durif, Franck [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Chazeron, Ingrid De [Auteur]
Université d'Auvergne - Clermont-Ferrand I [UdA]
CHU Clermont-Ferrand
Titre de la revue :
Scientific reports
Nom court de la revue :
Sci Rep
Numéro :
6
Pagination :
38152
Date de publication :
2016-12-01
ISSN :
2045-2322
Discipline(s) HAL :
Sciences cognitives
Résumé en anglais : [en]
Hallucinations have been described in various clinical populations, but they are neither disorder nor disease specific. In schizophrenia patients, hallucinations are hallmark symptoms and auditory ones are described as the ...
Lire la suite >Hallucinations have been described in various clinical populations, but they are neither disorder nor disease specific. In schizophrenia patients, hallucinations are hallmark symptoms and auditory ones are described as the more frequent. In Parkinson's disease, the descriptions of hallucination modalities are sparse, but the hallucinations do tend to have less negative consequences. Our study aims to explore the phenomenology of hallucinations in both hallucinating schizophrenia patients and Parkinson's disease patients using the Psycho-Sensory hAllucinations Scale (PSAS). The main objective is to describe the phenomena of these clinical symptoms in those two specific populations. Each hallucinatory sensory modality significantly differed between Parkinson's disease and schizophrenia patients. Auditory, olfactory/gustatory and cœnesthetic hallucinations were more frequent in schizophrenia than visual hallucinations. The guardian angel item, usually not explored in schizophrenia, was described by 46% of these patients. The combination of auditory and visual hallucinations was the most frequent for both Parkinson's disease and schizophrenia. The repercussion index summing characteristics of each hallucination (frequency, duration, negative aspects, conviction, impact, control and sound intensity) was always higher for schizophrenia. A broader view including widespread characteristics and interdisciplinary works must be encouraged to better understand the complexity of the process involved in hallucinations.Lire moins >
Lire la suite >Hallucinations have been described in various clinical populations, but they are neither disorder nor disease specific. In schizophrenia patients, hallucinations are hallmark symptoms and auditory ones are described as the more frequent. In Parkinson's disease, the descriptions of hallucination modalities are sparse, but the hallucinations do tend to have less negative consequences. Our study aims to explore the phenomenology of hallucinations in both hallucinating schizophrenia patients and Parkinson's disease patients using the Psycho-Sensory hAllucinations Scale (PSAS). The main objective is to describe the phenomena of these clinical symptoms in those two specific populations. Each hallucinatory sensory modality significantly differed between Parkinson's disease and schizophrenia patients. Auditory, olfactory/gustatory and cœnesthetic hallucinations were more frequent in schizophrenia than visual hallucinations. The guardian angel item, usually not explored in schizophrenia, was described by 46% of these patients. The combination of auditory and visual hallucinations was the most frequent for both Parkinson's disease and schizophrenia. The repercussion index summing characteristics of each hallucination (frequency, duration, negative aspects, conviction, impact, control and sound intensity) was always higher for schizophrenia. A broader view including widespread characteristics and interdisciplinary works must be encouraged to better understand the complexity of the process involved in hallucinations.Lire moins >
Langue :
Anglais
Audience :
Non spécifiée
Établissement(s) :
Université de Lille
CNRS
CHU Lille
CNRS
CHU Lille
Équipe(s) de recherche :
Équipe Psychiatrie & Croyance (PsyCHIC)
Date de dépôt :
2019-02-13T14:48:18Z
2020-02-11T15:57:38Z
2020-03-19T12:23:37Z
2020-02-11T15:57:38Z
2020-03-19T12:23:37Z
Fichiers
- hallucinations_schizophrenia_parkingson.pdf
- Version éditeur
- Accès libre
- Accéder au document